Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey

Access to bevacizumab, an important component of oncology treatment regimens, may be limited. This survey of oncologists in the US (n = 150), Europe (n = 230), and emerging markets (EM: Brazil, Mexico, and Turkey; n = 130) examined use of and barriers to accessing bevacizumab as treatment of advance...

Descripción completa

Detalles Bibliográficos
Autores principales: Monk, Bradley J., Lammers, Philip E., Cartwright, Thomas, Jacobs, Ira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374423/
https://www.ncbi.nlm.nih.gov/pubmed/28134851
http://dx.doi.org/10.3390/ph10010019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5374423/
https://www.ncbi.nlm.nih.gov/pubmed/28134851
http://dx.doi.org/10.3390/ph10010019

Ejemplares similares